Literature DB >> 6288403

Novel phenylpiperidine opioid antagonists and partial agonists: effects on fluid consumption.

J D Leander, J C Hart, M A Lochner, M D Hynes, D M Zimmerman.   

Abstract

The effects of five opioid antagonists, a racemate partial agonist and its agonist and antagonist optical isomers were studied on deprivation-induced drinking. All compounds had a phenylpiperidine nucleus. The antagonists produced dose-related decreases in drinking, and the potencies for decreasing drinking correlated with morphine-antagonist doses. The racemic partial agonist and its agonist isomer decreased drinking at doses higher than those which produced marked analgesia. Within the class of phenylpiperidine drugs studied, some had less specificity than naloxone for the mu-receptors as compared to the delta-receptor, but the suppression of drinking was not related to changes in mu-to-delta ratios.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288403     DOI: 10.1016/0014-2999(82)90436-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone.

Authors:  Victor J DeNoble; Paul C Mele
Journal:  Psychopharmacology (Berl)       Date:  2005-08-09       Impact factor: 4.530

2.  Importance of delta opioid receptors in maintaining high alcohol drinking.

Authors:  J C Froehlich; M Zweifel; J Harts; L Lumeng; T K Li
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Naloxone treatment attenuates food but not water intake in domestic pigeons.

Authors:  P Deviche; G Schepers
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 4.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.